Combating depression in Huntington's disease: effective antidepressive treatment with venlafaxine XR

被引:46
作者
Holl, Anna K. [1 ]
Wilkinson, Leonora [4 ]
Painold, Annamaria [1 ]
Holl, Etienne M. [2 ]
Bonelli, Raphael M. [3 ]
机构
[1] Graz Med Univ, Univ Clin Psychiat, A-8036 Graz, Austria
[2] Graz Med Univ, Univ Clin Neurosurg, A-8036 Graz, Austria
[3] Paracelsus Med Univ, Univ Clin Neurol, Salzburg, Austria
[4] UCL Inst Neurol, Sobell Dept Motor Neurosci & Movement Disorders, London WC1N 3BG, England
关键词
antidepressive treatment; depression; Huntington's disease; psychiatry; venlafaxine XR; AFFECTIVE-DISORDER; SUICIDE; RISK;
D O I
10.1097/YIC.0b013e3283348018
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Patients with Huntington's disease (HD) often suffer from psychiatric symptoms including affective disorder, psychosis, irritability, and apathy, which may be present in all stages of the disease. However - despite the obvious likelihood that these symptoms may be reduced by antidepressive treatments - to date, the effectiveness of such treatments in HD has only ever been examined in case studies. Twenty-six HD patients (17 men), with a diagnosis of major depression, were studied. The symptoms of HD and depression were systematically measured using the Beck Depression Inventory and the Hamilton Rating Scale for Depression both at baseline and after 4 weeks of treatment with venlafaxine XR. After 4 weeks of venlafaxine XR treatment, the symptoms of depression in HD patients decreased significantly relative to baseline. However, approximately one in five patients developed significant venlafaxine-related side effects (nausea and irritability). Venlafaxine XR is highly effective in the treatment of depression in HD, although it may produce unpleasant side effects. Further studies are required to establish the most suitable treatment for depression in HD. Int Clin Psychopharmacol 25:46-50 (C) 2010 Wolters Kluwer Health vertical bar Lippincott Williams & Wilkins.
引用
收藏
页码:46 / 50
页数:5
相关论文
共 33 条
  • [1] Symptomatic treatment of Huntington disease
    Adam, Octavian R.
    Jankovic, Joseph
    [J]. NEUROTHERAPEUTICS, 2008, 5 (02) : 181 - 197
  • [2] The effect of venlafaxine compared with other antidepressants and placebo in the treatment of major depression
    Bauer, Michael
    Tharmanathan, Puvan
    Volz, Hans-Peter
    Moeller, Hans-Juergen
    Freemantle, Nick
    [J]. EUROPEAN ARCHIVES OF PSYCHIATRY AND CLINICAL NEUROSCIENCE, 2009, 259 (03) : 172 - 185
  • [3] BAXTER LR, 1992, ARCH GEN PSYCHIAT, V49, P148
  • [4] Comparison of Beck Depression Inventories-IA and -II in psychiatric outpatients
    Beck, AT
    Steer, RA
    Ball, R
    Ranieri, WF
    [J]. JOURNAL OF PERSONALITY ASSESSMENT, 1996, 67 (03) : 588 - 597
  • [5] Huntington's disease: present treatments and future therapeutic modalities
    Bonelli, RM
    Wenning, GK
    Kapfhammer, HP
    [J]. INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 2004, 19 (02) : 51 - 62
  • [6] Mirtazapine in suicidal Huntington's disease
    Bonelli, RM
    [J]. ANNALS OF PHARMACOTHERAPY, 2003, 37 (03) : 452 - 452
  • [7] Craufurd D, 2001, NEUROPSY NEUROPSY BE, V14, P219
  • [8] Cummings J L, 1995, Adv Neurol, V65, P179
  • [9] FRONTAL-SUBCORTICAL CIRCUITS AND HUMAN-BEHAVIOR
    CUMMINGS, JL
    [J]. ARCHIVES OF NEUROLOGY, 1993, 50 (08) : 873 - 880
  • [10] Cunningham L A, 1997, Ann Clin Psychiatry, V9, P157, DOI 10.1023/A:1026277907818